• Something wrong with this record ?

Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study

R. Keil, M. Wasserbauer, Z. Zádorová, V. Kojecký, Š. Hlava, J. Št'ovíček, J. Chudý, M. Roznětinská, J. Drábek, N. Kubišová, J. Lochmannová,

. 2018 ; 53 (4) : 459-465. [pub] 20180321

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Observational Study

Persistent link   https://www.medvik.cz/link/bmc19000860

OBJECTIVES: Compliance to therapy is a key factor in the efficacy of treatment in clinical practice. The aim of our study was to evaluate the rate of compliance with mesalazine in patients with ulcerative colitis (UC), to examine risk factors of noncompliance and especially find ways on how adherence can be improved. MATERIALS AND METHODS: A total of 198 outpatients with UC completed two anonymous questionnaires including information on basic demographics, details of patient ́s disease and the use of mesalazine medication and quality of life. RESULTS: We found noncompliance (percentage of used medication per day less than 80%) with 5-ASA in 21.2% patients. Our study proved that the education level of patients significantly influenced the compliance of patients using mesalazine. A significant difference (p = .014) was found between the compliance of patients with secondary school education (84.1 ± 16.73) and those with university education (94.1 ± 9.9). The majority of patients preferred mesalazine once daily and are less likely to forget to take medication in the morning. Better quality of life was observed based on our data from WHOQOL-BREF questionnaire in statistically significant way in patients using concomitant therapy of immuosuppressive or biological therapy, lower daily doses and using sachets not tablets. CONCLUSIONS: Our study proved that compliance with mesalazine in patients with UC was related only to education level. If we target mesalazine therapy based on patient's preferences, we can improve the adherence with mesalazine. Our data could be beneficial for the treatment strategy in clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000860
003      
CZ-PrNML
005      
20231121144628.0
007      
ta
008      
190107s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/00365521.2018.1451915 $2 doi
035    __
$a (PubMed)29560753
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Keil, Radan $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic.
245    10
$a Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study / $c R. Keil, M. Wasserbauer, Z. Zádorová, V. Kojecký, Š. Hlava, J. Št'ovíček, J. Chudý, M. Roznětinská, J. Drábek, N. Kubišová, J. Lochmannová,
520    9_
$a OBJECTIVES: Compliance to therapy is a key factor in the efficacy of treatment in clinical practice. The aim of our study was to evaluate the rate of compliance with mesalazine in patients with ulcerative colitis (UC), to examine risk factors of noncompliance and especially find ways on how adherence can be improved. MATERIALS AND METHODS: A total of 198 outpatients with UC completed two anonymous questionnaires including information on basic demographics, details of patient ́s disease and the use of mesalazine medication and quality of life. RESULTS: We found noncompliance (percentage of used medication per day less than 80%) with 5-ASA in 21.2% patients. Our study proved that the education level of patients significantly influenced the compliance of patients using mesalazine. A significant difference (p = .014) was found between the compliance of patients with secondary school education (84.1 ± 16.73) and those with university education (94.1 ± 9.9). The majority of patients preferred mesalazine once daily and are less likely to forget to take medication in the morning. Better quality of life was observed based on our data from WHOQOL-BREF questionnaire in statistically significant way in patients using concomitant therapy of immuosuppressive or biological therapy, lower daily doses and using sachets not tablets. CONCLUSIONS: Our study proved that compliance with mesalazine in patients with UC was related only to education level. If we target mesalazine therapy based on patient's preferences, we can improve the adherence with mesalazine. Our data could be beneficial for the treatment strategy in clinical practice.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antiflogistika nesteroidní $x aplikace a dávkování $7 D000894
650    _2
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    _2
$a Česká republika $7 D018153
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a adherence k farmakoterapii $x psychologie $x statistika a číselné údaje $7 D055118
650    _2
$a mesalamin $x aplikace a dávkování $7 D019804
650    _2
$a lidé středního věku $7 D008875
650    _2
$a kvalita života $7 D011788
650    _2
$a rizikové faktory $7 D012307
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Wasserbauer, Martin, $u Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic. $d 1987- $7 xx0302700
700    1_
$a Zádorová, Zdena $u b 2nd Department of Internal Medicine , Charles University in Prague, FNKV , Czech Republic.
700    1_
$a Kojecký, Vladimír $u c Department of Internal Medicine , Regional Hospital of T.Bat'a , Zlín , Czech Republic.
700    1_
$a Hlava, Štěpán $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic.
700    1_
$a Št'ovíček, Jan $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic.
700    1_
$a Chudý, Jakub $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic.
700    1_
$a Roznětinská, Markéta $7 xx0248779 $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic.
700    1_
$a Drábek, Jiří $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic.
700    1_
$a Kubišová, Nikola $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic.
700    1_
$a Lochmannová, Jindra, $u a Department of Internal Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic. $d 1968- $7 xx0063944
773    0_
$w MED00010598 $t Scandinavian journal of gastroenterology $x 1502-7708 $g Roč. 53, č. 4 (2018), s. 459-465
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29560753 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20231121144625 $b ABA008
999    __
$a ok $b bmc $g 1364851 $s 1038983
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 53 $c 4 $d 459-465 $e 20180321 $i 1502-7708 $m Scandinavian journal of gastroenterology $n Scand J Gastroenterol $x MED00010598
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Logged in users only

Archiving options